Compare CNX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | ICUI |
|---|---|---|
| Founded | 1860 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.5B |
| IPO Year | 1998 | 1995 |
| Metric | CNX | ICUI |
|---|---|---|
| Price | $33.15 | $142.20 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $35.71 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.4M | 258.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | 100.62 |
| EPS | ★ 2.18 | 1.20 |
| Revenue | ★ $2,239,134,000.00 | $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.14 | $4.46 |
| P/E Ratio | ★ $14.73 | $119.05 |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.72 | $107.02 |
| 52 Week High | $43.62 | $160.29 |
| Indicator | CNX | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 65.17 |
| Support Level | $32.83 | $139.88 |
| Resistance Level | $34.00 | $142.31 |
| Average True Range (ATR) | 0.82 | 4.38 |
| MACD | -0.01 | 0.86 |
| Stochastic Oscillator | 25.47 | 85.31 |
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.